Business Context and Reporting Period
This Form 8-K is filed by Landec Corporation (not Lifecore Biomedical, Inc.) on September 9, 2011, reporting events occurring on that date and a press release issued on September 14, 2011. The filing addresses the termination of a material definitive agreement with Monsanto Company.
Key Financial Metrics
This filing does not report standard periodic financial metrics such as revenue, profit, cash flow, margins, or debt levels. The only specific financial figure disclosed is a contingent termination fee.
- Termination Fee: $4 million payable by Monsanto to Landec upon the expiration of the License Agreement.
Material Changes
The primary material change is the notification from Monsanto that it intends to allow the Amended and Restated License, Supply and R&D Agreement to expire on December 1, 2011. Key consequences include:
- Reversion of all rights to the Intellicoat seed coating technology back to Landec.
- Landec's entitlement to receive the $4 million termination fee.
Outlook, Risks, and Management Commentary
Management has disclosed the termination via a press release (Exhibit 99.1) incorporated by reference. The filing notes that the expiration of the agreement is in accordance with its terms. No specific forward-looking guidance regarding future revenue streams or operational outlook is provided in this text, other than the recovery of technology rights and the receipt of the termination fee.
Investor Verification Checklist
- Verify the exact terms of the $4 million termination fee payment schedule and conditions.
- Confirm the status of the Intellicoat technology rights reversion process.
- Review the attached press release (Exhibit 99.1) for additional management commentary not included in the 8-K text.
- Assess the impact of losing the Monsanto supply agreement on future revenue projections.